Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45, ENTR-601-50, and ENTR-601-51, which are in preclinical trial, for the treatment of Duchenne muscular dystrophy; and PTI-501, an intracellular thymidine phosphorylase enzyme replacement therapy for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. It has strategic collaboration and license agreements with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize VX-670; and Pierrepont Therapeutics, Inc. to advance the development of PTI-501. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Entrada Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Akebia Therapeutics (AKBA – Research Report), FibroG...

Analysts Are Bullish on Top Healthcare Stocks: Akebia Therapeutics (AKBA), FibroGen (FGEN)

Entrada Therapeutics Inc ( ($TRDA) ) has released its Q3 earnings. Here is a breakdown of the information Entrada Therapeutics Inc presented to its...

Entrada Therapeutics Reports Increased Losses Amid R&D Expansion

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

Current Quarter	$-1.06	Next Quarter	$-1.09
Current Year	$-3.59	Next Year	$-4.33
QoQ Growth	-2.8%	YoY Growth	-20.6%
3Y EPS CAGR	+30.4%	Target Price	$16.50
Consensus	Buy	Upside	+63.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TRDA	$10.11	+10.25%	352.35K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TRDA	$10.11	+10.3%	352.35K
3
4
5
6

TRDA

TRDA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Entrada Therapeutics Inc. Data in Excel

Get Entrada Therapeutics Inc. Data in Excel